Company Profile

Gerologix Inc
Profile last edited on: 5/12/2023      CAGE: 82SW1      UEI: RKMBWNJPJ473

Business Identifier: New therapies for age-?related muscle loss
Year Founded
2018
First Award
2019
Latest Award
2019
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

721 Michaels Creek
Evans, GA 30809
   (706) 414-1732
   N/A
   www.gerologix.com
Location: Single
Congr. District: 12
County: Columbia

Public Profile

Organized around the concept of healthy aging, Gerologix is addressing advancement of the discovery of new therapies to prevent the muscle loss that occurs with aging. Identifying novel pathways of aging, the firm's principals are constantly identifying new mechanisms of action associated with loss of muscle strength and muscle function. Drug Discovery image45 We work with chemists and biologists to develop new small molecules that can block age-related changes in multiple organ systems. Our Strategy We are an early stage biotechnology company focused on the prevention and treatment of age-related muscle loss (sarcopenia). Our current pipeline includes small molecules that target various aspects of the kynurenine pathway, a key pathway involved in aging.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 1 NIH $223,673
Project Title: Novel Small Molecules for the Treatment of Sarcopenia

Key People / Management

  Mark Hamrick

  Carlos Isales

  Ling Ruan

  Kathryn Smith

Company News

There are no news available.